{"id":31121,"date":"2025-02-24T17:33:00","date_gmt":"2025-02-24T12:03:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31121"},"modified":"2025-05-01T15:11:15","modified_gmt":"2025-05-01T09:41:15","slug":"parkinsons-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment","title":{"rendered":"The Parkinson\u2019s Treatment Landscape: Progressing Too Slowly for an Expanding Patient Base"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fa69bbb6dd0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fa69bbb6dd0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\/#Current_Parkinsons_disease_treatment_market_landscape\" >Current Parkinson\u2019s disease treatment market landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\/#Barriers_to_progress_in_the_Parkinsons_disease_therapeutics_market\" >Barriers to progress in the Parkinson\u2019s disease therapeutics market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\/#Existing_Parkinsons_disease_treatment_strategies\" >Existing Parkinson\u2019s disease treatment strategies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\/#Future_of_Parkinsons_therapy\" >Future of Parkinson\u2019s therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\/#Market_reaction_and_future_prospects_of_Parkinsons_disease_treatment\" >Market reaction and future prospects of Parkinson\u2019s disease treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Parkinson\u2019s disease, a progressive neurodegenerative disorder, is emerging as a significant health challenge in the United States and globally, primarily due to an aging population. This condition, characterized by motor symptoms such as tremors, muscle rigidity, and slowed movement, along with numerous non-motor symptoms, reduces quality of life and affects independence. According to DelveInsight\u2019s analysis, <strong>more than 1 million<\/strong> people in the United States alone are <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\">diagnosed with Parkinson\u2019s disease<\/a>, with nearly <strong>3 million<\/strong> patients across the seven major markets,<strong> <\/strong>including<strong> <\/strong>the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. This widespread impact highlights pressing gaps in diagnostics and treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-parkinson-s-disease-treatment-market-landscape\"><span class=\"ez-toc-section\" id=\"Current_Parkinsons_disease_treatment_market_landscape\"><\/span><strong>Current Parkinson\u2019s disease treatment market landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The present-day situation poses a paradox revealing a troubling reality: as the number of patients and the demand for improved treatments increase, progress in Parkinson\u2019s disease innovation has slowed. <em>Why is advancement lagging despite the clear and growing need for effective solutions?<\/em><\/p>\n\n\n\n<p><strong><em>Read our blog and find out <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-treatments\"><strong><em>How close are we to a Cure for Parkinson\u2019s disease<\/em><\/strong><\/a><\/p>\n\n\n\n<p>Despite various advancements, Parkinson\u2019s disease still lacks a cure. Existing therapies are predominantly designed as palliative treatments that often bring significant side effects, including hallucinations and cognitive impairment, which make long-term treatment challenging. Additionally, the absence of reliable diagnostic tools for early detection adds to the difficulty, as Parkinson\u2019s symptoms are often confused with other neurodegenerative conditions, such as multiple system atrophy, corticobasal degeneration, dementia with Lewy bodies, and progressive supranuclear palsy. These overlapping symptoms often lead to misdiagnoses, delaying effective treatment and negatively affecting patient outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-barriers-to-progress-in-the-parkinson-s-disease-therapeutics-market\"><span class=\"ez-toc-section\" id=\"Barriers_to_progress_in_the_Parkinsons_disease_therapeutics_market\"><\/span><strong>Barriers to progress in the Parkinson\u2019s disease therapeutics market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As per DelveInsight analysis, one primary obstacle is the lack of <strong>disease-modifying treatments (DMTs) or curative therapies<\/strong>. While recent advancements have introduced new symptomatic treatments and devices, they do not address disease progression. Many ongoing therapies focus on alleviating symptoms rather than slowing the disease\u2019s progression. Furthermore, if new therapies do not significantly improve upon existing options, market differentiation may be limited. The increasing use of off-label treatments also influences market share and profitability, ultimately affecting overall revenue.<\/p>\n\n\n\n<p>Additionally, despite growing awareness, the persistent <strong>social stigma<\/strong> surrounding Parkinson\u2019s disease remains a significant barrier to progress in both patient well-being and treatment adoption. This stigma often leads to isolation, delays in seeking care, and reluctance to pursue available therapies, hindering optimal treatment outcomes. Addressing these societal challenges is crucial for enhancing patient engagement and ensuring that advancements in the market translate into a better quality of life for those affected by the disease.<\/p>\n\n\n\n<p>Another major hurdle in advancing <a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapy-market\">new therapies for Parkinson\u2019s disease<\/a> lies in navigating the <strong>complex regulatory landscape<\/strong>. <em>Why do so many promising therapies face significant delays on their path to approval?<\/em> The approval process demands rigorous proof of safety and efficacy, a requirement that can discourage companies from pursuing innovative treatments. <strong>Supernus Pharmaceuticals<\/strong> offers a recent example: after over two years of persistence and regulatory setbacks, including the issuance of Complete Response Letters (CRLs), the FDA finally accepted their New Drug Application for <strong>SPN-830<\/strong> in <strong>August 2024<\/strong>.<\/p>\n\n\n\n<p>Such regulatory challenges might be due to the intricate nature of Parkinson\u2019s itself. Researchers continue to investigate its cellular and molecular roots, but the disease\u2019s complexity makes it difficult to pinpoint precise therapeutic targets, slowing down drug discovery and development efforts. The result is a slow-paced pipeline, as companies must grapple not only with scientific unknowns but also with the high-stakes regulatory environment before bringing novel treatments to patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-existing-parkinson-s-disease-treatment-strategies\"><span class=\"ez-toc-section\" id=\"Existing_Parkinsons_disease_treatment_strategies\"><\/span><strong>Existing Parkinson\u2019s disease treatment strategies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><em>The current <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><em>Parkinson\u2019s disease market<\/em><\/a><em> was valued at nearly <\/em><strong><em>USD 3 billion<\/em><\/strong><em> in 2023 across the 7MM, with the United States accounting for the largest share.<\/em><\/p>\n\n\n\n<p>However, navigating Parkinson\u2019s disease treatment often centers around one mainstay: <strong>levodopa<\/strong>. Levodopa has been a crucial part of Parkinson\u2019s treatment since its introduction, known as the \u201cgold standard\u201d for managing motor symptoms. <em>However, what makes levodopa so vital, and why has not a new, more advanced therapy replaced it?<\/em> All these questions still circle the paradigm of Parkinson\u2019s disease. Despite its widespread use, levodopa\u2019s limitations, particularly the risk of severe side effects, highlight a pressing need for innovative solutions in Parkinson\u2019s care.<\/p>\n\n\n\n<p>For many, Levodopa is the most effective way to manage symptoms, especially early in the disease. But, the reality is more complex as patients rely on levodopa over the years, and adverse effects can surface. Hallucinations and confusion, especially in elderly patients or those with cognitive challenges, complicate treatment. Moreover, as per our secondary analysis, after four to six years on levodopa, nearly 40% of patients experience motor fluctuations, a significant hurdle in long-term management. These side effects often push doctors to explore alternative treatments, such as dopamine-receptor agonists, which activate dopamine receptors directly without converting to dopamine.<\/p>\n\n\n\n<p>Combination and other therapies currently hold a dominant position in the market. The promising trajectory of these therapies is largely driven by their capacity to address the complexity of Parkinson\u2019s through a multi-targeted approach. By leveraging synergistic effects, combination therapies provide enhanced efficacy and flexibility across a variety of diseases, making them especially appealing in managing multifaceted health issues. This trend underscores a growing industry focus on innovative treatments, highlighting combination therapies as a key area for future therapeutic and commercial developments.<\/p>\n\n\n\n<p>Additionally, several <strong>dopamine agonists<\/strong> are on the market, including brands like <strong>Requip, Mirapex, and Apokyn<\/strong>, which are now available in generic forms. In addition, with generic versions prevalent, they lack the novelty that might offer breakthroughs for patients needing more durable, tolerable options.<\/p>\n\n\n\n<p>The Parkinson\u2019s market offers numerous <a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapeutic-market\">approved Parkinson\u2019s disease therapies<\/a>, including generics that have been available for over a decade. In August 2024, the US FDA approved <strong>CREXONT<\/strong>, an extended-release formulation of carbidopa and levodopa for Parkinson\u2019s disease. Additionally, <strong>Amneal Pharmaceuticals<\/strong> ensures that eligible patients can access prescription coverage through the Amneal Patient Assistance Program. At the same time, CoverMyMeds streamlines prior authorization for healthcare providers and pharmacists to improve patient access.<\/p>\n\n\n\n<p>Similarly, in <strong>October 2024<\/strong>, the US FDA approved <strong>VYALEV<\/strong> (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour continuous infusion therapy for motor fluctuations in adults with advanced Parkinson\u2019s disease. VYALEV demonstrated superior improvement in &#8220;on&#8221; time without troublesome dyskinesia compared to oral immediate-release carbidopa\/levodopa.&nbsp;<\/p>\n\n\n\n<p>This therapy also offers personalized dosing throughout the day, addressing the progressive nature of Parkinson&#8217;s disease, where oral medications often become ineffective. However, it is worth noting that <strong>VYALEV<\/strong> is a combination therapy that includes levodopa, a well-established treatment with no novel molecules, which limits its potential to bring groundbreaking innovation to the market.<\/p>\n\n\n\n<p>Despite the presence of several approved Parkinson\u2019s disease therapies across the 7MM, current treatment options for Parkinson\u2019s disease still fall short of providing comprehensive efficacy. As the market for Parkinson\u2019s disease treatment continues to expand, these unmet needs highlight the urgent demand for innovative therapies that address both symptom management and disease progression holistically.<\/p>\n\n\n\n<p><em>So, the question remains why has not a newer, more targeted therapy emerged?<\/em> As the field advances, the need for innovative therapies that go beyond symptom relief creates an opportunity for researchers and pharmaceutical companies to redefine Parkinson\u2019s treatment.<\/p>\n\n\n\n<p><strong><em>Dive deep to understand more about the <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-treatment-market\"><strong><em>Most Promising Therapies in the Parkinson\u2019s Disease Treatment Market<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-of-parkinson-s-therapy\"><span class=\"ez-toc-section\" id=\"Future_of_Parkinsons_therapy\"><\/span><strong>Future of Parkinson\u2019s therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments. Several companies are advancing novel drug candidates, such as <strong>Translational Inhibitors of Neurotoxic Aggregating Proteins (TINAPs) <\/strong>and<strong> Sigma-1 Receptor (SIGMAR1) agonists,<\/strong> which have the potential to address unmet needs. Industry leaders like <strong>Supernus Pharmaceuticals, Cerevel Therapeutics, LLC, and Pharma Two B,<\/strong> among others, are poised to lead the market during the forecast period (2025\u20132034), given their early-stage advancements and promising therapies, positioning them to secure a competitive edge over others in this evolving landscape.<\/p>\n\n\n\n<p>Among the leading <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights\">Parkinson\u2019s disease drug candidates in development<\/a>, <strong>Solengepras (CVN424)<\/strong>, a dopamine D2 receptor modulator, is expected to potentially secure a significant share of the total Parkinson\u2019s market across the 7MM by 2034. On the other hand, <strong>UCB0599<\/strong>, developed by <strong>UCB Biopharma <\/strong>and<strong> Novartis<\/strong>, is anticipated to enter the market by <strong>2028<\/strong>.<\/p>\n\n\n\n<p>A comprehensive assessment of emerging drug assets in the pipeline for Parkinson\u2019s disease, along with detailed analyses, is available in the final report provided by DelveInsight. This report covers anticipated drug candidates and projected launch timelines and provides in-depth analytical insights into each asset\u2019s potential impact on the market.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-67407902-7fff-8ce5-ab09-5f25a1c5b4d6\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"207\" \/><col width=\"158\" \/><col width=\"140\" \/><col width=\"102\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"4\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Comparison of Emerging Drugs for Parkinson&rsquo;s Treatment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 25.95pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">MoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Phase<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 25pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SPN-830&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(apomorphine infusion pump)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Supernus Pharmaceuticals, Inc.\/Britannia Pharmaceutical<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Dopamine receptor agonist<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 48.05pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Tavapadon<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">AbbVie\/Cerevel Therapeutics, LLC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">D1\/D5 selective partial agonist<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 20.15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">P2B001<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(extended-release pramipexole and rasagiline)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pharma Two B<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Dopamine receptor agonist and MAO-B inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 9.95pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"4\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">The pipeline for Parkinson&rsquo;s is robust, with assets in the early and late phases of development.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_reaction_and_future_prospects_of_Parkinsons_disease_treatment\"><\/span><strong>Market reaction and future prospects of Parkinson\u2019s disease treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite significant progress in Parkinson\u2019s disease treatment, critical unfulfilled gaps continue. There is an urgent demand for therapies that go beyond symptom management to slow disease progression actively. Recognizing the problem leading industry players are heavily investing in innovative research and advancing novel drug candidates targeting cellular pathways involved in neurodegeneration.<\/p>\n\n\n\n<p>Moreover, opportunities are also emerging through strategic collaborations. In February 2024, for instance, <strong>Amneal Pharmaceuticals<\/strong> entered into an exclusive licensing agreement with <strong>Zambon Biotech SA<\/strong> for <strong>IPX203<\/strong> in the EU, UK, and Switzerland. This partnership not only aims to introduce new therapeutic options to the European markets but also highlights the value of collaborative efforts in expanding research scope and accessibility.&nbsp;<\/p>\n\n\n\n<p>Similarly, in <strong>January 2025<\/strong> at the <a href=\"https:\/\/www.delveinsight.com\/blog\/jp-morgan-healthcare-conference\"><strong>J.P. Morgan Healthcare Conference (JPM25)<\/strong><\/a><strong>,<\/strong> <strong>Johnson &amp; Johnson<\/strong> revealed a definitive agreement to acquire <strong>Intra-Cellular Therapies<\/strong>. Intra-Cellular Therapies specializes in developing and marketing treatments for central nervous system (CNS) disorders, including Parkinson&#8217;s disease. Such partnerships, acquisitions, and licensing agreements could accelerate development, enabling innovative treatments to reach patients more rapidly.<\/p>\n\n\n\n<p>In parallel, companies are exploring combination therapies and new formulations to improve treatment efficacy and consistency. Through ongoing collaborations and a strengthened clinical pipeline, the industry is moving towards holistic solutions and is poised for substantial growth by 2034.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"Parkinson's Disease Market Outlook\" class=\"wp-image-30639\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson\u2019s disease, a progressive neurodegenerative disorder, is emerging as a significant health challenge in the United States and globally, primarily due to an aging population. This condition, characterized by motor symptoms such as tremors, muscle rigidity, and slowed movement, along with numerous non-motor symptoms, reduces quality of life and affects independence. According to DelveInsight\u2019s analysis, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":31123,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16778,19134,19133,19131,19925,17566],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-31121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-parkinsons-disease-4","tag-parkinsons-disease-clinical-trials","tag-parkinsons-disease-pipeline","tag-parkinsons-disease-treatment","tag-parkinsons-treatment","tag-parkinsons-clinical-trials","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Parkinson\u2019s Treatment: Struggling to Keep Pace with Patient Needs<\/title>\n<meta name=\"description\" content=\"The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parkinson\u2019s Treatment: Struggling to Keep Pace with Patient Needs\" \/>\n<meta property=\"og:description\" content=\"The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T12:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-01T09:41:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Parkinson\u2019s Treatment: Struggling to Keep Pace with Patient Needs","description":"The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment","og_locale":"en_US","og_type":"article","og_title":"Parkinson\u2019s Treatment: Struggling to Keep Pace with Patient Needs","og_description":"The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments.","og_url":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-24T12:03:00+00:00","article_modified_time":"2025-05-01T09:41:15+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment","url":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment","name":"Parkinson\u2019s Treatment: Struggling to Keep Pace with Patient Needs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment.png","datePublished":"2025-02-24T12:03:00+00:00","dateModified":"2025-05-01T09:41:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The Parkinson\u2019s disease therapeutics market is seeing a dynamic pipeline with numerous competitors developing innovative treatments.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/parkinsons-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment.png","width":466,"height":284,"caption":"parkinsons-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/24100727\/parkinsons-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinsons Clinical Trials<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease treatment<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s treatment<\/span>","<span class=\"advgb-post-tax-term\">Parkinsons Clinical Trials<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 24, 2025","modified":"Updated on May 1, 2025"},"absolute_dates_time":{"created":"Posted on Feb 24, 2025 5:33 pm","modified":"Updated on May 1, 2025 3:11 pm"},"featured_img_caption":"parkinsons-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31121"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31121\/revisions"}],"predecessor-version":[{"id":31127,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31121\/revisions\/31127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31123"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31121"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31121"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}